Keytruda meets OS, PFS endpoints in first-line NSCLC

Merck & Co. Inc. (NYSE:MRK) added $3.41 to $62.07 on Tuesday after it said Keytruda pembrolizumab met the co-primary endpoints in the Phase III KEYNOTE-189 trial as first-line treatment of metastatic non-squamous non-small cell lung cancer. The move translates to a $9.3 billion increase in market cap. With the readout, investors are now more

Read the full 546 word article

User Sign In